Login to Your Account

Affitech's AT001 Enters Clinic, as Delisting Looms

By Cormac Sheridan
Staff Writer

Wednesday, August 22, 2012
Clinical testing of Affitech A/S's lead antibody, AT001/r84, began this week, just as the company enters its final weeks as a publicly quoted entity and prepares to become a private entity, wholly owned by Russian investors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription